Showing results (201-210 of 366) with videos related to
Sort By:
Pageof 37
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Nature Communications|September 6, 2017
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerKirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.European Journal of Cancer (Oxford, England : 1990)|May 29, 2026
Quality and safety of research biopsies in oncology clinical trialsPaolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerNasser Altorki, Maureen E Lane, Thomas Bauer, et al.European Journal of Cancer (Oxford, England : 1990)|February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancerManuel Cobo, Dolores Isla, Bartomeu Massuti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.Pageof 37